{"id":145824,"date":"2023-08-31T13:05:02","date_gmt":"2023-08-31T11:05:02","guid":{"rendered":"https:\/\/investmentbell.com\/?p=145824"},"modified":"2023-08-31T13:05:06","modified_gmt":"2023-08-31T11:05:06","slug":"sage-therapeutics-to-cut-40-of-jobs-after-depression-drug-setback","status":"publish","type":"post","link":"https:\/\/investmentbell.com\/fr\/news\/stocks\/sage-therapeutics-to-cut-40-of-jobs-after-depression-drug-setback\/","title":{"rendered":"Sage Therapeutics va supprimer 40% d&#039;emplois apr\u00e8s le revers d&#039;un m\u00e9dicament contre la d\u00e9pression"},"content":{"rendered":"<p>(Reuters) &#8211; Sage Therapeutics said on Thursday it would cut its workforce by about 40%, weeks after the U.S. health regulator declined to approve its drug to treat major depressive disorder.<\/p>\n\n\n\n<p>The U.S. Food and Drug Administration (FDA) in early August approved the company and partner Biogen (NASDAQ:BIIB)&#8217;s pill for postpartum depression, but rejected it as a treatment for major depressive disorder, which is a much larger market.<\/p>\n<div class=\"rate-now\"><span id=\"rate-mypost145824\"><\/span> <span id=\"rate-points\"> 0<\/span><\/div>\n\t\t\t<script type=\"text\/javascript\">jQuery('#rate-mypost145824').raty({\n\t\t\t\thalfShow : true,\n\t\t\t\thalf: true,readOnly: true,score: 0,\n\t\t\t\tpath: \"https:\/\/investmentbell.com\/wp-content\/plugins\/userpro-rating\/images\/\"\n\t\t\t\t});<\/script>","protected":false},"excerpt":{"rendered":"<p>(Reuters) &#8211; Sage Therapeutics said on Thursday it would cut its workforce by about 40%, weeks after the U.S. health regulator declined to approve its drug to treat major depressive disorder. The U.S. Food and Drug Administration (FDA) in early August approved the company and partner Biogen (NASDAQ:BIIB)&#8217;s pill for postpartum depression, but rejected it [&hellip;]<\/p>","protected":false},"author":13,"featured_media":145825,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[23],"tags":[],"class_list":{"0":"post-145824","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-stocks"},"_links":{"self":[{"href":"https:\/\/investmentbell.com\/fr\/wp-json\/wp\/v2\/posts\/145824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/investmentbell.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/investmentbell.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/investmentbell.com\/fr\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/investmentbell.com\/fr\/wp-json\/wp\/v2\/comments?post=145824"}],"version-history":[{"count":1,"href":"https:\/\/investmentbell.com\/fr\/wp-json\/wp\/v2\/posts\/145824\/revisions"}],"predecessor-version":[{"id":145826,"href":"https:\/\/investmentbell.com\/fr\/wp-json\/wp\/v2\/posts\/145824\/revisions\/145826"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/investmentbell.com\/fr\/wp-json\/wp\/v2\/media\/145825"}],"wp:attachment":[{"href":"https:\/\/investmentbell.com\/fr\/wp-json\/wp\/v2\/media?parent=145824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/investmentbell.com\/fr\/wp-json\/wp\/v2\/categories?post=145824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/investmentbell.com\/fr\/wp-json\/wp\/v2\/tags?post=145824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}